Details of the Drug

General Information of Drug (ID: DM08RE5)

Drug Name
TAK-280
Synonyms MVC-280
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
TTD ID
DHN9I5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B7 homolog 3 (CD276) TT6CQUM CD276_HUMAN Not Available [1]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Aggressive cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B7 homolog 3 (CD276) DTT CD276 3.92E-01 -0.04 -0.81
B7 homolog 3 (CD276) DTT CD276 7.33E-02 -0.53 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.